

A cohort study to find Incidence  
of Peripheral Arterial Disease in  
Thailand from EGAT study  
**(I-PAD EGAT)**

Uraporn Jaowattana, MD  
Fellowship in Cardiology,  
Ramathibodi Hospital


# Background and Rationale

- Peripheral Arterial Disease (PAD) is one of burden diseases
- Systemic atherosclerosis
- Causes morbidity and mortality worldwide
- PAD is considered to be an established CAD equivalent.
- By year 2020, PAD will surely be one of the globally burden diseases.

# Poor Outcomes of PAD

- **Chronic Limb Ischemia (CLI)**: is pain in lower extremity at rest or ulceration with or without tissue necrosis.
- **Acute Limb Ischemia (ALI)** : presents within hours with rest limb pain and a pulseless, painful foot. The vessel is occluded with a thrombus on top of mild to severe lesions. ALI is a result from plaque rupture followed by in situ thrombosis or migration of a clot from proximal location.

# PAD mortality : 10-year survival rates the San Diego Artery Study




Criqui MH *et al.* *N Engl J Med* 1992;326:381–386.

- In USA, the incidence of symptomatic Peripheral Vascular Disease(PVD) increases with age

-from about 0.3% per year for men aged 40–55 years to about 1% per year for men aged over 75 years.

- In Thailand, the study data on PAD is still scant, even we had been enrolled in the REACH registry trial.

# REACH Study( n= 68,236)



# PAD burden internationally

- REACH STUDY
- Reduction of Atherothrombosis for Continued Health (REACH) Registry
- 68,236 patients with either known atherosclerotic arterial disease (n= 55,814) or at least had 3 risk factors for atherothrombosis (n=12,422)
- from 5,587 practices in 44 countries in December 2003- June 2004.



# PAD Prevalence

- 18.3% in UK
- 19.1% in Netherlands
- 18% in Germany and Sweden, ranging from 3.7-16.6% in US from different studies
- 19.8% in China
- 11.7% in Saudi Arabic
- 10.5% in Spain
- 29.3% in South Africa
- 3.2% South India
- **5.2% in Thailand**

Review: Ethnicity and peripheral artery disease ,Q J Med 2009; 102:3–16

Sritara, P. International Epidemiology Journal, 2003.

# REACH Study

- Demonstrated that PAD patients had high prevalence of underlying vascular disease, multiple atherothrombotic risk factors.
- Found that there was underutilization in treating cardiovascular risk

- PAD prevalence in Thailand 5.2% \*

\* Sritara, P. International Epidemiology Journal, 2003.

# EGAT 2002

- In Thailand, from EGAT employee
- Overall prevalence of PAD was 5.2% ,with finding of 4% in male and 9% in female.
- Hypertension, women, current smoking, current alcohol drinking and overweight have been found to be significant predictors of PAD

- **Incidence of PAD from EGAT populations**

# I-PAD EGAT

- **Inclusion Criteria:** All of the Employee from previous EGAT study population in 2002

# I-PAD EGAT

- **Exclusion:** Loss of contact and not followed up in this study

# Objectives

- **Primary objective**
  - To find PAD incidence from EGAT study
- **Secondary objectives**
  - To estimate prevalence of PAD from EGAT
  - To assess influence of RFs on new PAD development
  - To find mean CAVI value ( indicate arterial stiffness)



# Methodology

- Cohort study

**EGAT study subjects  
without PAD at  
2002.**



**Follow-up on  
PAD diagnosis  
at year 2012.**

# Populations

## Population

Elderly age 50-74, middle-class, urban

## Study sample

All EGAT employee who are available in former and this EGAT study.

# Definition

- Peripheral artery disease (PAD)
- Year 10<sup>th</sup> PAD
- Cumulative 10 years PAD

# Operational Definitions

PAD	Lowest resting ABI<0.9
Asymptomatic PAD	PAD + no leg symptom
IC <sup>i</sup>	
-Typical	<b>Calf pain while walking</b> <b>Disappears in 10 min after standing still</b> <b>Never occurs at rest</b>
-Atypical	Exertional leg pain other than calf

<sup>i</sup>Rose GA. Bull WHO 1962;27:645-58.

# Operational Definitions

Diabetes <sup>i</sup>	FBG $\geq$ 126 mg/dl or on hypoglycemic Rx
Hypercholesterolaemia <sup>ii</sup>	TC $\geq$ 240 mg/dl or on lipid-lowering Rx
Hypertension <sup>iii</sup>	Systolic BP $\geq$ 140 mmHg or diastolic BP $\geq$ 90 mmHg or on antihypertensive Rx

<sup>i</sup>ADA. Diabetes Care 2000;23(Suppl 1):s20-3

<sup>ii</sup>NCEP III. JAMA 2001;285:2486-97

<sup>iii</sup>1999 WHO/ISH. J Hypertens 2001;19(12):2285-8

# Operational Definitions

Thais

Individuals who had lived in Thailand for  $\geq 17$  yrs

Current smoker

Individuals who currently smoke  $\geq 1$  cigarette per day for at least 1 yr

Current alcohol drinker

Individuals who currently take  $\geq 1$  drink of alcohol beverage at least once a month for at least 1 yr

# I-PAD EGAT

- **Diagnosis of Peripheral Arterial Disease:**

ABI  $<0.9$  is made for the diagnosis of PAD in this study.

- normal ABI (1.11-1.40)

# ABI

ADA & AHA

5 min rest, quiet and supine

Angle probe 60 degrees


Move probe back & forth

Inflate  $\geq 20$  mmHg

Slow deflation: 2mmHg/sec

Syst BP: 1<sup>st</sup> signal during deflation

ADA & AHA. Circulation 1993;88(2):819-28



Pocket Doppler  
MINIDOP ES100VX











● EXAMINATION RESULT (GENERAL)


 PREVIOUS EXAM

DATE/TIME 14D12M2012Y 8H18M07S   
EXAM TYPE PULSE WAVE BASIC  
ID 1234  
AGE 24 YRS SEX FEMALE  
RESULT Estimated age of artery is 20-24.  
R-CAVI: 5.8 /L-CAVI: 5.7  
R-ABI: 1.00 Normal.  
L-ABI: 1.06 Normal.

**GENERAL** RESULT *BPB* WAVEFORM VALUE  
REWRITE PRINTOUT SEND PC  RETURN   
DISPLAY RESULT



ID: 1234  
 NAME: SOMETHAI WATTANACHAI  
 HEIGHT: 154.0cm WEIGHT: 55.0kg SEX: FEMALE AGE: 24YRS  
 DATE/TIME: 14/12/2012 08:18:07



ID: 1234  
 NAME: SOMETHAI WATTANACHAI  
 HEIGHT: 154.0cm WEIGHT: 55.0kg SEX: FEMALE AGE: 24YRS  
 DATE/TIME: 14/12/2012 08:18:07

TEST: I, II, III, aVR, aVL, aVF, V1, V2, V3, V4, V5, V6  
 STIFFNESS: 5.8  
 DE ARTERY: 5.8  
 RR-BP: 100 / 72 mmHg  
 PP: 34

DE ARTERY	RR	BB	TR
R-CAV	100mm	118ms	218ms
L-CAV	100ms	121ms	221ms

ID: 1234  
 NAME: SOMETHAI WATTANACHAI  
 HEIGHT: 154.0cm WEIGHT: 55.0kg SEX: FEMALE AGE: 24YRS  
 DATE/TIME: 14/12/2012 08:18:07

TEST	STIFFNESS	DE ARTERY	RR-BP	PP	COMMENTS
I, II, III, aVR, aVL, aVF, V1, V2, V3, V4, V5, V6	5.8	5.8	100 / 72	34	Estimated age of artery is 20-24.
R-AB1	1.00	1.00	100 / 72	34	Normal.
L-AB1	1.00	1.00	100 / 72	34	Normal.

RR: 100 (bpm)  
 RR: 100 (bpm)  
 BP (S/D): 100 / 72  
 PP: 34 MAP: 88  
 RR: 100 (bpm)  
 BP (S/D): 100 / 72  
 PP: 34 MAP: 88



LBS (mmHg):  
 BP (S/D): 108 / 67  
 PP: 41 MAP: 83  
 LA (mmHg):  
 BP (S/D): 115 / 65  
 PP: 50 MAP: 81  
 L-AB1: 1.00  
 L-CAV: 5.7

R-AB1: 1.00  
 R-CAV: 5.8

# Statistical Methods

- Descriptive statistic (mean, SD, percent) for subject characteristics explanation and incidence analysis.
- KS-test for normal distribution test.
- Z-test to demonstrate mean of ABI and CAVI.
- Paired T-test to test difference b/w  $ABI_{2002}$  and  $ABI_{2012}$ , ABI and CAVI at 2012
- Univariate and multivariate logistic regression for demonstrating the predictor of peripheral artery disease (PAD) in elderly.

# Statistical Methods


- Univariate and multivariate logistic regression for demonstrating the predictor of peripheral artery disease (PAD) in elderly.



# Study Results

**2002**

**2,209 EGAT employee  
No PAD from normal ABI**



**2012**

**1,427 with previous normal ABI  
1,387 with complete data of ABI this year  
follow up**



**1,427 EGAT study employee  
who had no peripheral artery disease at 2002  
(ABI  $\geq$ 0.9)**

**40 subjects were excluded  
because of unavailable  
ABI at 2012.**

**A total 1,387 employee for research analysis.**

# Baseline ABI

- 38 subjects (2.74%) from 1,387 subjects that they had  $ABI < 0.9$  at 2012.
- 38 subjects were considered as the subjects who had peripheral artery disease for this research.
- Normal distribution test  
>> Not acceptable  
(K-S test, 2002 p-value 0.001 and 2012 p-value  $< 0.001$ )



# 10-years PAD Incidence

- Unstandardized : 2.74 % (n=1,387)
- Age-adjusted : 2.86% (based on n= 80,642)
- Sex-adjusted: 2.65% (based on n=2,418)

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
<b>Age at 2002 (years) (n=1,387)</b>		<b>59 <math>\pm</math> 5</b>		
<b>Age group(n=1,387)</b>	<b>50-54 Y</b>		<b>294</b>	<b>21.20%</b>
	<b>55-59</b>		<b>560</b>	<b>40.37%</b>
	<b>60-64</b>		<b>337</b>	<b>24.30%</b>
	<b>equal or more than 65</b>		<b>196</b>	<b>14.13%</b>
<b>Gender (n=1,387)</b>	<b>Female</b>		<b>1029</b>	<b>74.19%</b>
	<b>Male</b>		<b>358</b>	<b>25.81%</b>
<b>Hypertension (n=1,387)</b>	<b>Have no hypertension</b>		<b>594</b>	<b>42.83%</b>
	<b>Have hypertension</b>		<b>793</b>	<b>57.17%</b>
<b>Smoking (n=1,370)</b>	<b>Nonsmoker</b>		<b>664</b>	<b>48.47%</b>
	<b>Smoker (Both current and former)</b>		<b>706</b>	<b>51.53%</b>
<b>Diabetes mellitus (n=1,384)</b>	<b>Have no Diabetes mellitus</b>		<b>1080</b>	<b>78.03%</b>
	<b>Have Diabetes mellitus</b>		<b>304</b>	<b>21.97%</b>

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
Stroke (n=1,387)	Have not experienced stroke		1360	98.05%
	Have experienced stroke		27	1.95%
Dyslipidemia (n=1,387)	Have no dyslipidemia		449	32.37%
	Have dyslipidemia		938	67.63%
Coronary artery stenosis (n=1,387)	Have no previous coronary artery stenosis		1310	94.45%
	Have previous coronary artery stenosis		77	5.55%
Previous myocardial infarction (n=1,387)	Have no previous MI		1374	99.06%
	Have previous MI		13	0.94%
Weight (kg) (n=1,361)		64.20 $\pm$ 10.75		
Height (cm) (n=1,361)		161.55 $\pm$ 7.65		
BMI (kg/m <sup>2</sup> ) (n=1,361)		24.59 $\pm$ 3.74		
BMI (n=1,361)	Normal (BMI < 25)		788	57.90%
	Overweight (30 > BMI $\geq$ 25)		489	35.93%
	Obesity (BMI $\geq$ 30)		84	6.17%

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
Age risk (n=1,387)	Male $\leq$ 55 and Female $\leq$ 65 years		1031	74.33%
	Male > 55 and Female > 65 years		356	25.67%
Chronic Kidney Disease (n= 1,387)	No CKD as underlying disease		1350	97.33%
	Have CKD as underlying disease		37	2.67%
GFR (ml/min) (n=1,370)		67.69 $\pm$ 20.93		
GFR (n=1,370)	Normal GFR		846	61.75%
	Abnormal GFR (< 60 ml/min)		524	38.25%
Blood pressure test assessment (n=1,377)	Normal BP both assessments		1002	72.77%
	High BP >140/90 for 2 times of assessments.		375	27.23%



## Baseline of cardiovascular risks characteristics

	Mean $\pm$ SD	n	n %
<b>Resting blood pressure assessment</b> <i>1<sup>st</sup> blood pressure assessment (n= 1,382)</i>			
<b>Systolic blood pressure (mmHg)</b>	<b>133 <math>\pm</math> 19</b>		
<b>Systolic blood pressure</b> SBP1 Normal		<b>915</b>	<b>66.21%</b>
SBP1 >140 mmHg		<b>467</b>	<b>33.79%</b>
<b>Dystolic blood pressure (mmHg)</b>	<b>77 <math>\pm</math> 11</b>		
<b>Dystolic blood pressure</b> DBP1 normal		<b>1220</b>	<b>88.28%</b>
DBP1 > 90 mmHg		<b>162</b>	<b>11.72%</b>
<b>Blood pressure</b> Normal BP1		<b>876</b>	<b>63.39%</b>
Abnormal BP1 (>140/90)		<b>506</b>	<b>36.61%</b>

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
<b>2<sup>nd</sup> blood pressure assessment (n= 1,377)</b>		<b>133 <math>\pm</math> 19</b>		
<b>Systolic blood pressure (mmHg)</b>				
<b>Systolic blood pressure</b>	<b>SBP2 Normal</b>		<b>937</b>	<b>68.05%</b>
	<b>SBP2 &gt;140 mmHg</b>		<b>440</b>	<b>31.95%</b>
<b>Dystolic blood pressure (mmHg)</b>		<b>77 <math>\pm</math> 11</b>		
<b>Dystolic blood pressure</b>	<b>DBP2 normal</b>		<b>1227</b>	<b>89.11%</b>
	<b>DBP2 &gt; 90 mmHg</b>		<b>150</b>	<b>10.89%</b>
<b>Blood pressure</b>	<b>Normal BP2</b>		<b>899</b>	<b>65.29%</b>
	<b>Abnormal BP2 (&gt;140/90)</b>		<b>478</b>	<b>34.71%</b>

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
<b>Cardio-Ankle Vascular Index 2012 (CAVI) (n=1,377)</b>				
<b>Right CAVI score</b>		<b>9.06 <math>\pm</math> 1.22</b>		
<b>Left CAVI score</b>		<b>8.97 <math>\pm</math> 1.22</b>		
<b>CAVI criteria</b>	<b>Normal (CAVI score 8.0)</b>		<b>175</b>	<b>12.71%</b>
	<b>Border line (9 &gt; CAVI <math>\geq</math>8 )</b>		<b>402</b>	<b>29.19%</b>
	<b>Possible CAVI <math>\geq</math>9 Arteriosclerosis</b>		<b>800</b>	<b>58.10%</b>
<b>Ankle Brachial Index at 2002</b>				
<b>Ankle Brachial Index</b>	<b>Normal</b>		<b>1,387</b>	<b>100.00%</b>
<b>(n=1,387)</b>	<b>Abnormal (ABI &lt;0.9)</b>		<b>0</b>	<b>0.00%</b>
<b>Ankle Brachial Index at 2012</b>				
<b>Ankle Brachial Index</b>	<b>Normal</b>		<b>1349</b>	<b>97.26%</b>
<b>(n=1,387)</b>	<b>Abnormal (ABI &lt;0.9)</b>		<b>38</b>	<b>2.74%</b>

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
<b>Ankle Brachial Index at 2002</b>				
Left Ankle Brachial Index (n=1,387)		1.10 $\pm$ 0.09		
Left Ankle Brachial Index	Normal		1,387	100.00%
	Abnormal (ABI <0.9)		0	0.00%
<hr/>				
Right Ankle Brachial Index (n=1,387)		1.12 $\pm$ 0.10		
Right Ankle Brachial Index	Normal		1,387	100.00%
	Abnormal (ABI <0.9)		0	0.00%
<hr/>				
Ankle Brachial Index	Normal		1,387	100.00%
(n=1,387)	Abnormal (ABI <0.9)		0	0.00%
<hr/>				
<b>Ankle Brachial Index at 2012</b>				
Left Ankle Brachial Index (n=1,387)		1.11 $\pm$ 0.10		
Right Ankle Brachial Index (n=1,387)		1.12 $\pm$ 0.09		
<hr/>				
Ankle Brachial Index	Normal		1349	97.26%
(n=1,387)	Abnormal (ABI <0.9)		38	2.74%

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
<b>Fasting blood glucose (FBS) and HbA1C Test</b>				
<b>Fasting blood glucose (FBS) (mg/dl) Test (n=1,386)</b>		<b>99 <math>\pm</math> 22</b>		
<b>Fasting blood glucose</b>	<b>Normal</b>		<b>1261</b>	<b>90.98%</b>
	<b>Abnormal (FBS <math>\geq</math>126)</b>		<b>125</b>	<b>9.02%</b>
<b>HbA1C (n=1,386)</b>		<b>6.0 <math>\pm</math> 0.8</b>		
<b>HbA1C</b>	<b>Normal</b>		<b>1204</b>	<b>86.87%</b>
	<b>Abnormal (HbA1C <math>&gt;</math> 6.5%)</b>		<b>182</b>	<b>13.13%</b>

## Baseline of cardiovascular risks characteristics

		Mean $\pm$ SD	n	n %
<b>Lipid profile test</b>				
<b>Total Cholesterol (n=1,386)</b>		<b>204 <math>\pm</math> 44</b>		
<b>Cholesterol level</b>	<b>Less than 240 mg/dL</b>		<b>1109</b>	<b>80.01%</b>
	<b>Equal or more than 240 mg/dL</b>		<b>277</b>	<b>19.99%</b>
<b>Triglyceride (n=1,386)</b>		<b>121 <math>\pm</math> 61</b>		
<b>Triglyceride level</b>	<b>Less than 200 mg/dL</b>		<b>1266</b>	<b>91.34%</b>
	<b>Equal or more than 200 mg/dL</b>		<b>120</b>	<b>8.66%</b>
<b>HDLC (n=1,386)</b>		<b>59 <math>\pm</math> 16</b>		
<b>HDLC level</b>	<b>Equal or more than 40 mg/dL</b>		<b>1293</b>	<b>93.29%</b>
	<b>Less than 40 mg/dL</b>		<b>93</b>	<b>6.71%</b>
<b>LDLC (n=1,386)</b>		<b>132 <math>\pm</math> 40</b>		
<b>LDLC level</b>	<b>Less than 160 mg/dL</b>		<b>1079</b>	<b>77.85%</b>
	<b>Equal or more than 160 mg/dL</b>		<b>307</b>	<b>22.15%</b>
<b>Lipid Profile test (n=1,386)</b>	<b>Normal lipid profile test</b>		<b>931</b>	<b>67.17%</b>
	<b>Abnormal lipid profile test</b>		<b>455</b>	<b>32.83%</b>

# Univariate analysis

## Demonstrate predictors of year 10<sup>th</sup> PAD

**Univariate logistic regression results:**

**>> Significant risks of Year 10<sup>th</sup> PAD**

- 1. Dyslipidemia**
- 2. Male with more 55 or female more 65 years**
- 3. Chronic kidney disease**
- 4. FBS equal or more than 126 mg/dl**
- 5. HbA1C more than 6.5%**
- 6. Triglyceride equal or more than 200 mg/dl**
- 7. HDLC less than 40 mg/dl**
- 8. Stroke History**

# Univariate analysis results

Risks		N	Year 10 PAD		Odd ratio	95%CI	p-Value
			n	(%)			
<b>Age</b>		<b>1,387</b>	<b>38</b>	<b>2.77%</b>	<b>1.077</b>	<b>1.013 to 1.145</b>	<b>0.018*</b>
Age group (n=1,387)	50-54 Y	294	7	2.38%		Reference	
	55-59	560	9	1.61%	0.670	0.247 to 1.817	0.431
	60-64	337	13	3.86%	1.645	0.647 to 4.180	0.295
	equal or more than 65	196	9	4.59%	1.973	0.722 to 5.389	0.185
Gender (n=1,387)	Female	1029	26	2.53%		Reference	
	Male	358	12	3.35%	1.338	0.668 to 2.680	0.412
Hypertension (n=1,387)	Have no hypertension	594	11	1.85%		Reference	
	Have hypertension	793	27	3.40%	1.868	0.919 to 3.797	0.084
Smoking (n=1,370)	Nonsmoker	664	15	2.26%		Reference	
	Smoker	706	23	3.26%	1.457	0.754 to 2.817	0.263
Diabetes mellitus (n=1,384)	No	1080	25	2.31%		Reference	
	Yes	304	12	3.95%	1.734	0.861 to 3.494	0.123



# Univariate analysis

## Demonstrate predictors of year 10<sup>th</sup> PAD

Risks		N	Year 10 PAD		Odd ratio	95%CI	p-Value
			n	(%)			
Stroke (n=1,387)	No	1360	35	2.57%		Reference	
	Yes	27	3	11.11%	4.732	1.361 to 16.455	0.015
Dyslipidemia (n=1,387)	No	449	5	1.11%		Reference	
	Yes	938	33	3.52%	3.238	1.256 to 8.351	0.015
Previous CAD (n=1,387)	No	1307	38	2.77%			
	Yes	80	0	0.00%	-	-	-
BMI (n=1,361)	Normal weight	788	16	2.03%		Reference	
	Over weight	489	17	3.48%	1.738	0.870 to 3.472	0.118
	Obesity	84	2	2.38%	1.177	0.266 to 5.209	0.830
Male > 55 or Female > 65 years (n=1,387)	No	1031	23	2.23%		Reference	
	Yes	356	15	4.21%	1.928	0.994 to 3.737	0.052
CKD (n= 1,387)	No CKD	1350	33	2.44%		Reference	
	Have CKD	37	5	13.51%	6.236	2.285 to 17.016	<0.001

# Univariate analysis

## Demonstrate predictors of year 10<sup>th</sup> PAD

Risks	N	Year 10 PAD		Odd ratio	95%CI	p-Value
		n	(%)			
GFR (n=1,370)	>=60 ml/min	846	17	2.01%	Reference	0.073
	< 60 ml/min	524	19	3.63%	1.835	
BP assessment (2times) (n=1,377)	<=140/90 mmHg	1002	25	2.50%	Reference	0.329
	>140/90 mmHg	375	13	3.47%	1.403	
Fasting blood glucose (n=1,386)	< 126 mg/dl	1261	28	2.22%	Reference	<0.001
	>=126 mg/dl	125	10	8.00%	3.829	
HbA1C (n=1,386)	<=6.5%	1204	26	2.16%	Reference	0.001
	> 6.5%	182	12	6.59%	3.198	
FBS /HbA1C (n=1,386)	< 126 mg/dl and <=6.5%	1166	25	2.14%	Reference	0.003
	>=126 mg/dl and/or > 6.5%	220	4	3.01%	2.866	

# Univariate analysis

## Demonstrate predictors of year 10<sup>th</sup> PAD

Risks		N	Year 10 PAD		Odd ratio	95%CI	p-Value
			n	(%)			
Cholesterol level (n=1,386)	< 240 mg/dL	1109	30	2.71%	1.070	Reference 0.485 to 2.360	0.868
	>= 240 mg/dL	277	8	2.89%			
Triglyceride level (n=1,386)	< 200 mg/dL	1266	30	2.37%	2.943	Reference 1.318 to 6.573	0.008
	>= 200 mg/dL	120	8	6.67%			
HDLC level (n=1,386)	>= 40 mg/dL	1293	29	2.24%	4.670	Reference 2.141 to 10.185	<0.001
	< 40 mg/dL	93	9	9.68%			
LDLC level (n=1,386)	<160 mg/dL	1079	27	2.50%	1.448	Reference 0.710 to 2.953	0.309
	>= 160 mg/dL	307	11	3.58%			
Lipid Profile test (n=1,386)	Normal	931	19	2.04%	2.092	Reference 1.096 to 3.991	0.025
	Abnormal	455	19	4.18%			

# Multivariate analysis

- **Multivariate logistic regression analysis, backward stepwise method**
- **Predictors from univariate analysis with  $p$ -value  $< 0.10$  were entered in the multivariate analysis**
  1. **Age**
  2. **Hypertension**
  3. **Dyslipidemia**
  4. **Male with more 55 or female more 65 years**
  5. **Chronic kidney disease**
  6. **GFR abnormality**
  7. **Triglyceride abnormality**
  8. **HDLC abnormality**
  9. **Fasting blood sugar or HbA1C abnormality**
  10. **Stroke/TIA History**

**A total 1,370 subjects who had completed data were analyzed.**

# Multivariate analysis

The significant predictors of year 10<sup>th</sup> PAD were


1. Chronic kidney disease
2. FBS  $\geq$ 126 mg/dl and/or HbA1C  $>$  6.5%
3. Dyslipidemia
4. HDL-cholesterol ( $<$ 40 mg/dL)
5. Stroke /TIA history

Age also was a important factor.

# Multivariate analysis

	<b>B</b>	<b>S.E.</b>	<b>Wald</b>	<b>Sig.</b>	<b>Odd ratio</b>	<b>95 % C.I.</b>	
<b>Age2002</b>	<b>0.065</b>	<b>0.034</b>	<b>3.583</b>	<b>0.058*</b>	<b>1.067</b>	<b>0.998</b>	<b>1.142</b>
<b>Dyslipidemia</b>	<b>1.319</b>	<b>0.545</b>	<b>5.856</b>	<b>0.016*</b>	<b>3.738</b>	<b>1.285</b>	<b>10.877</b>
<b>HDL &lt; 40 mg/dL</b>	<b>1.405</b>	<b>0.424</b>	<b>10.996</b>	<b>0.001*</b>	<b>4.074</b>	<b>1.776</b>	<b>9.344</b>
<b>FBS &gt;=126 mg/dl and/or HbA1C &gt; 6.5%</b>	<b>0.924</b>	<b>0.366</b>	<b>6.365</b>	<b>0.012*</b>	<b>2.520</b>	<b>1.229</b>	<b>5.168</b>
<b>Chronic kidney disease</b>	<b>1.397</b>	<b>0.554</b>	<b>6.355</b>	<b>0.012*</b>	<b>4.041</b>	<b>1.365</b>	<b>11.970</b>
<b>Stroke</b>	<b>1.554</b>	<b>0.660</b>	<b>5.545</b>	<b>0.019*</b>	<b>4.732</b>	<b>1.298</b>	<b>17.257</b>
<b>Constant</b>	<b>-9.131</b>	<b>2.160</b>	<b>17.862</b>	<b>0.000</b>	<b>0.000</b>		

## Relationship between changes of ABI and PAD



**Mean different Changes of ABI for ten years (n=1,387)**

$$-0.04 \pm 0.12$$

**95%CI= -0.05 to -0.04**

The changes of ABI were divided in to 3 equal groups at

**Percentiles 33.33 = -0.08 and Percentiles 66.67 = 0.01**

**Group 1** ABI increased from baseline more than 0.01.

**Group 2** ABI increased from baseline equal or less than 0.01 but not decreased from baseline more than 0.08.

**Group 3** ABI decreased from baseline equal or more than 0.08.

## Relationship between changes of ABI and PAD

Pearson chi-square used for analysis relationship between PAD and changes of ABI.

The previous ABI changes group 1 and group 2 were integrated into the same group.

Group 1 =ABI decreased from baseline less than 0.08

Group 2= ABI decreased from baseline equal or more than 0.08

		2012							
		ABI > = 0.9 Considered as no PAD (N=1,349)				ABI < 0.9 considered as PAD (N=38)			
		Count	Row N %	Column N %	Table N %	Count	Row N %	Column N %	Table N %
ABI 2012	Decreased < 0.08 (N= 857)	886	99.89 %	65.68%	63.88%	1	0.11%	2.63%	0.07%
	Decreased > = 0.08 (N=481)	463	92.60 %	34.32%	33.38%	37	7.40%	97.37%	2.67%

Pearson chi-square analysis shown significant difference between PAD and ABI changes (*p-value* <0.001).



## Relationship between changes of ABI and Risk factors

- Relationship between the ABI changes groups and 5 significant risks of PAD from multivariate analysis were also analyzed by Pearson chi-square.
- The results shown significant relation between HDL-Cholesterol level and the ABI changes groups (*p-value* = 0.024) and between fasting blood sugar level and/or HbA1C > 6.5% and the ABI changes groups (*p-value* = 0.027).

Changes of ABI		N	Column N		<i>p-value</i> <sup>a</sup>
			Group 1 ABI decreased from baseline less than 0.08.	Group 2 ABI decreased from baseline equal or more than 0.08	
Peripheral artery disease diagnosed at next 10 years	No	1349	886 (65.7%)	463 (34.3%)	<b>&lt;0.001*</b>
	Yes	38	1 (2.6%)	37(97.4%)	
Stroke	No	1360	873(64.2%)	487(35.8%)	0.263
	Yes	27	14(51.9%)	13 (48.1%)	
Dyslipidemia	No	449	282 (62.81%)	167 (37.19%)	0.579
	Yes	938	605 (64.5%)	333 (35.5%)	
Chronic kidney disease	No	1350	869 (64.4%)	481 (35.6%)	0.073
	Yes	37	18 (48.6%)	19 (51.4%)	
HDLC < 40 mg/dL	No	1293	838 (64.8%)	455 (35.2%)	<b>0.025*</b>
	Yes	93	49(52.7%)	44(47.3%)	
FBS >=126 mg/dl and/or HbA1C > 6.5%	No	1166	761(65.3%)	405 (34.7%)	<b>0.029*</b>
	Yes	220	126 (57.3%)	94 (42.7%)	

## Relationship between Cardio-ankle vascular index (CAVI) and PAD

- **Cardio-ankle vascular index (CAVI) mean between patients with PAD and without PAD was compared by t-test.**
- **There was no significant difference of CAVI between the patients who had PAD diagnosed by ABI.**

Cardio-ankle vascular index	Peripheral artery disease diagnosed		<i>p-value</i>
	ABI $\geq$ 0.9 No	ABI $<$ 0.9 Yes	
n	1,339	38	0.575 <sup>a</sup>
Mean $\pm$ SD	9.18 $\pm$ 1.25	9.37 $\pm$ 1.98	
N of Age adjusted	78,663	2,303	
Mean $\pm$ SD	9.21 $\pm$ 1.25	9.42 $\pm$ 1.95	$<0.001^*$
<b><i>Cardio-ankle vascular index criteria</i> N(%)</b>			
Normal (CAVI $<$ 8.0)	175	169 (96.6%)	6 (3.4%)
Border line and (9 $>$ CAVI $\geq$ 8 )	402	390 (97.0%)	12 (3.0%)
Possible Arteriosclerosis (CAVI $\geq$ 9)	800	780 (97.5%)	20 (2.5%)

<sup>a</sup>t-test <sup>b</sup>Pearson chi-square

# Conclusion

- Incidence of PAD diagnosed by abnormal ABI  $<0.9$ , in the past 10 years from EGAT population was 2.74%.

# Univariate analysis

- **Significant RFs for year 10<sup>th</sup> PAD were dyslipidemia ,male with more 55 or female more 65 years, CKD, FBS  $\geq 126$  mg/dl, HbA1C  $> 6.5\%$  ,Triglyceride  $\geq 200$  mg/d,HDL  $< 40$  mg/dl,stroke history**

# Multivariate analysis

The significant predictors of year 10<sup>th</sup> PAD were

1. Chronic kidney disease
  2. FBS  $\geq$ 126 mg/dl and/or HbA1C  $>$  6.5%
  3. Dyslipidemia
  4. HDL-cholesterol ( $<$ 40 mg/dL)
  5. Stroke /TIA history
- Age was also important.

- Delta change of ABI
  - When the change value decreases more than 0.08 , it relates to the development of PAD in the next 10 years.
  - Risk factors: FBS  $\geq$  126mg/dl, HDL $<$ 40 mg/dl

## Limitations of the study

- There is no ethnicity difference.
- This represents only the middle-class populations for Thailand
- Limited number of patients who have been followed up in both times.

# Special Thanks and Acknowledgement

- อาจารย์นพ ปิยะมิตร และ อาจารย์พญ ชนิกา ศิริธรา
- อาจารย์นพ สุกิจ แต้มวงษ์
- อาจารย์นพ ปริญญา วาทีสาธกกิจ
- ทีมงานวิจัย **EGAT**